Amgen (AMGN) : Zacks Investment Research ranks Amgen (AMGN) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 10 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 15 research analysts is 2.37, which indicates as a Buy.
Amgen (AMGN) has been rated by 11 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $209 and the lowest price target forecast is $157. The average forecast of all the analysts is $185.73 and the expected standard deviation is $15.69.
Also, Gabelli & Co. initiates coverage on Amgen (NASDAQ:AMGN) The brokerage firm has issued a Hold rating on the shares. The rating by the firm was issued on August 26, 2016.
Amgen (NASDAQ:AMGN): After opening at $170.04, the stock dipped to an intraday low of $169.47 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $173.3864 and the buying power remained strong till the end. The stock closed at $172.64 for the day, a gain of 1.47% for the day session. The total traded volume was 2,931,367. The stocks close on the previous trading day was $170.14.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.